Vorasidenib for Certain IDH-Mutant Gliomas: Is It Worth It?

Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a “breakthrough,” whereas others call the approval “premature.”
Medscape Medical News

source https://www.medscape.com/viewarticle/vorasidenib-certain-idh-mutant-gliomas-it-worth-it-2024a1000lvu?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?